General Biologicals Corporation (GBC) has announced that it has made significant progress on PAC-113, also known as P113. GBC has added new products into its P113 product portfolio and received positive research results for second generation P113 compounds. New skin care products have been added to the P113 product lines. Currently, the P113 product portfolio includes oral mouthrinse solution, oral mouth spray, feminine cleansing wash, feminine soothing spray, as well as anti-bacterial hand cream. These non-prescription OTC products can be purchased at pharmacy stores in Taiwan and online. GBC is expanding its distribution channels and developing additional products including P113 products specifically targeted at the relief of dry mouth symptoms. Two new compounds called P113Du and P113Tri have been identified as the next generation P113 antimicrobial peptides. Based on a research study conducted by Institute of Molecular and Cellular Biology and Department of Life Sciences of National Tsing Hua University, Taiwan in collaboration with GBC, P113Du and P113Tri contained significant fractions of a-helix conformation and were less sensitive to high salt and low pH than P113. These new antimicrobial compounds exhibited increased antifungal activity against planktonic, biofilm cells and clinical isolates of C.albicans and non-albicans Candida spp. The study results suggest that P-113Du and P-113Tri are promising candidates for development as novel antifungal agents.